Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.1 GBX | +2.28% | +7.45% | -3.81% |
Mar. 26 | Scancell doses first patient in melanoma-focused trials | AN |
Mar. 22 | Seneca Growth Capital announces tepid 2023 results | AN |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 80.96M 102M |
---|---|---|---|---|---|
Net income 2024 * | -14M -17.62M | Net income 2025 * | -14M -17.62M | EV / Sales 2024 * | - |
Net Debt 2024 * | 3.88M 4.88M | Net Debt 2025 * | 14.94M 18.8M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-5.49
x | P/E ratio 2025 * |
-6.53
x | Employees | 51 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.52% |
1 day | +2.28% | ||
1 week | +7.45% | ||
Current month | +13.23% | ||
1 month | +2.54% | ||
3 months | -8.18% | ||
6 months | -14.95% | ||
Current year | -3.81% |
Managers | Title | Age | Since |
---|---|---|---|
Linda Durrant
CEO | Chief Executive Officer | 67 | 96-12-31 |
Director of Finance/CFO | 38 | 23-08-28 | |
Fayaz Master
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 65 | 23-01-31 | |
Ursula Ney
BRD | Director/Board Member | 72 | 19-10-22 |
Linda Durrant
CEO | Chief Executive Officer | 67 | 96-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 10.1 | +2.28% | 327 157 |
24-05-13 | 9.875 | 0.00% | 371,718 |
24-05-10 | 9.875 | +1.80% | 214,593 |
24-05-09 | 9.7 | -1.77% | 577,398 |
24-05-08 | 9.875 | +5.05% | 762,868 |
Delayed Quote London S.E., May 14, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.81% | 102M | |
+29.79% | 48.16B | |
-1.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+10.00% | 25.59B | |
-22.91% | 18.96B | |
+8.24% | 12.92B | |
+28.92% | 12.03B | |
-2.08% | 11.77B |
- Stock Market
- Equities
- SCLP Stock